Rhumbline Advisers Denali Therapeutics Inc. Transaction History

Rhumbline Advisers

  • $113 Billion
  • Q2 2025

A detailed history of Rhumbline Advisers transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 212,503 shares of DNLI stock, worth $3.17 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
212,503
Previous 190,256 11.69%
Holding current value
$3.17 Million
Previous $2.59 Million 14.88%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 12, 2025
BUY
$11.47 - $16.65 $255,173 - $370,412
22,247 Added 11.69%
212,503 $2.97 Million
Q1 2025

Apr 08, 2025
SELL
$13.6 - $23.59 $1,822 - $3,161
-134 Reduced 0.07%
190,256 $2.81 Million
Q4 2024

May 29, 2025
BUY
$20.24 - $31.58 $2,712 - $4,231
134 Added 0.07%
190,390 $3.88 Million
Q4 2024

Jan 30, 2025
BUY
$20.24 - $31.58 $10,059 - $15,695
497 Added 0.26%
190,390 $3.88 Million
Q3 2024

Nov 12, 2024
SELL
$20.96 - $31.05 $104,087 - $154,194
-4,966 Reduced 2.55%
189,893 $5.53 Million
Q2 2024

Aug 01, 2024
BUY
$14.96 - $23.22 $342,584 - $531,738
22,900 Added 13.32%
194,859 $4.52 Million
Q1 2024

May 09, 2024
BUY
$15.83 - $23.35 $82,252 - $121,326
5,196 Added 3.12%
171,959 $3.53 Million
Q4 2023

Feb 08, 2024
SELL
$16.2 - $23.18 $38,248 - $54,727
-2,361 Reduced 1.4%
166,763 $3.58 Million
Q3 2023

Nov 09, 2023
BUY
$20.63 - $30.17 $147,339 - $215,474
7,142 Added 4.41%
169,124 $3.49 Million
Q2 2023

Aug 08, 2023
BUY
$23.37 - $32.96 $370,180 - $522,086
15,840 Added 10.84%
161,982 $4.78 Million
Q1 2023

May 11, 2023
BUY
$21.91 - $32.67 $70,331 - $104,870
3,210 Added 2.25%
146,142 $3.37 Million
Q4 2022

Feb 14, 2023
BUY
$26.28 - $33.92 $394,173 - $508,766
14,999 Added 11.72%
142,932 $3.98 Million
Q3 2022

Nov 10, 2022
BUY
$25.97 - $38.53 $271,594 - $402,946
10,458 Added 8.9%
127,933 $3.93 Million
Q2 2022

Aug 11, 2022
BUY
$20.88 - $35.19 $424,490 - $715,412
20,330 Added 20.93%
117,475 $3.46 Million
Q1 2022

May 12, 2022
BUY
$29.0 - $47.27 $14,384 - $23,445
496 Added 0.51%
97,145 $3.13 Million
Q4 2021

Feb 10, 2022
SELL
$42.59 - $55.02 $32,198 - $41,595
-756 Reduced 0.78%
96,649 $4.31 Million
Q3 2021

Nov 12, 2021
BUY
$48.48 - $78.23 $123,623 - $199,486
2,550 Added 2.69%
97,405 $4.91 Million
Q2 2021

Aug 05, 2021
BUY
$50.3 - $78.44 $1.17 Million - $1.83 Million
23,280 Added 32.53%
94,855 $7.44 Million
Q1 2021

May 06, 2021
SELL
$53.8 - $81.53 $432,982 - $656,153
-8,048 Reduced 10.11%
71,575 $4.09 Million
Q4 2020

Feb 10, 2021
BUY
$36.89 - $93.56 $19,477 - $49,399
528 Added 0.67%
79,623 $6.67 Million
Q3 2020

Nov 12, 2020
SELL
$23.13 - $38.84 $273,396 - $459,088
-11,820 Reduced 13.0%
79,095 $2.83 Million
Q2 2020

Aug 13, 2020
BUY
$16.01 - $28.82 $400,009 - $720,067
24,985 Added 37.9%
90,915 $2.2 Million
Q1 2020

May 06, 2020
BUY
$14.2 - $27.98 $34,335 - $67,655
2,418 Added 3.81%
65,930 $1.15 Million
Q4 2019

Feb 05, 2020
BUY
$14.4 - $19.99 $11,260 - $15,632
782 Added 1.25%
63,512 $1.11 Million
Q3 2019

Oct 23, 2019
SELL
$15.32 - $21.92 $10,065 - $14,401
-657 Reduced 1.04%
62,730 $961,000
Q2 2019

Aug 14, 2019
BUY
$18.5 - $28.14 $59,274 - $90,160
3,204 Added 5.32%
63,387 $1.32 Million
Q1 2019

May 01, 2019
SELL
$17.99 - $24.65 $11,981 - $16,416
-666 Reduced 1.09%
60,183 $1.4 Million
Q4 2018

Jan 31, 2019
BUY
$13.88 - $21.75 $315,242 - $493,986
22,712 Added 59.55%
60,849 $1.26 Million
Q3 2018

Nov 07, 2018
BUY
$12.46 - $21.74 $273,197 - $476,671
21,926 Added 135.25%
38,137 $829,000
Q2 2018

Aug 06, 2018
BUY
$15.25 - $21.02 $35,166 - $48,472
2,306 Added 16.58%
16,211 $247,000
Q1 2018

May 02, 2018
BUY
$15.36 - $24.8 $213,580 - $344,844
13,905 New
13,905 $274,000

Others Institutions Holding DNLI

# of Institutions
247
Shares Held
135M
Call Options Held
148K
Put Options Held
15.4K
View Full List

About Denali Therapeutics Inc.

DNLI Quotes by TradingView
  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email